Physician profile

Vicky Snyder

Family · Alcoa, TN

NPI 1386814622

$7,638.15

in general payments reported to CMS, 2019-2025

39 companies · $2,771 in 2025

The $2,771 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$5,977.69
Education$68.88

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Lilly USA, LLC $1,093.79 2021-2025 Mounjaro, Jardiance, Zepbound
Novo Nordisk INC $818.29 2021-2025 Ozempic, Rybelsus, Wegovy
Dexcom, INC. $702.89 2021-2025 Dexcom G6 Transmitter
Amgen INC. $578.04 2021-2025 Evenity, Repatha, Repatha
Xeris Pharmaceuticals, INC. $439.95 2021-2025 Gvoke Hypopen, Recorlev
Insulet Corporation $392.40 2022-2025 Omnipod, Omnipod
Cequr Corporation $390.68 2024-2025 Cequr Simplicity
Radius Health, INC. $359.00 2023-2025 Tymlos
Corcept Therapeutics $335.08 2023-2025 Korlym
Sequel Med Tech, LLC $280.32 2025 Twiist
Sanofi-Aventis U.S. LLC $259.91 2021-2024
Medtronic, INC. $250.01 2022-2025 Minimed 780g, Inpen Smart Insulin Delivery System
Beta Bionics, INC. $211.21 2023-2025 Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach
Tandem Diabetes Care, INC. $195.41 2023-2025 T:Slim X2 Insulin Pump With Control-Iq
Boehringer Ingelheim Pharmaceuticals, INC. $158.62 2022-2025 Jardiance
Show all 39 companies
CompanyGeneral paymentsYearsTop products
Novartis Pharmaceuticals Corporation $133.35 2022-2025
Abbott Laboratories $108.67 2022-2025 Freestyle Libre 3, Eterna
Ibsa Pharma INC. $102.61 2021-2022
Esperion Therapeutics, INC. $94.02 2021-2025 Nexletol
Astrazeneca Pharmaceuticals Lp $80.94 2021-2023 Lokelma
Amneal Pharmaceuticals LLC $74.40 2024-2025 Unithroid
Abbvie INC. $67.58 2022-2024
Bayer Healthcare Pharmaceuticals INC. $57.14 2022
Kyowa Kirin, INC. $52.08 2023-2024 Crysvita
Amphastar Pharmaceuticals, INC. $50.81 2025
Ascensia Diabetes Care US INC. $48.40 2023
Zealand Pharma US, INC. $46.20 2021
Intra-Sana Laboratories $37.58 2024 Reltone 200 Mg, Glycate, Reltone 400 Mg
Tolmar, INC. $31.98 2024
Mannkind Corporation $31.34 2021-2025
Sanofi US Services INC. $24.74 2024
Antares Pharma, INC. $19.84 2024 Xyosted
Kowa Pharmaceuticals America, INC. $18.69 2023 Livalo
Pfizer INC. $17.29 2025
Clarus Therapeutics INC. $15.91 2021
Almatica Pharma LLC $15.09 2024 Loreev Xr
Daiichi Sankyo INC. $15.07 2022
Horizon Therapeutics Plc $14.77 2023 Tepezza
Takeda Pharmaceuticals U.S.A., INC. $14.05 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Vicky Snyder

$7,638.15

in general payments reported 2019-2025

Years
2021-2025
Top company
Lilly USA, LLC
Context
The $2,771 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).

https://glasscript.com/doctor/10523931/vicky-snyder

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.